Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders Growth (5y) (2014 - 2026)
Powered by 
Analysis
Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.60 Bn | 38.94 Bn | 2.15 Bn |
| 2 | Viatris | 19.15 Bn | 18.27 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.49 Bn | 5.36 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.35 Bn | 516.55 Mn | 2.10 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 996.17 Mn | 706.05 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 404.39 Mn | 363.15 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -18.96% |
| Mar 31, 2026 | -44.65% |
| Dec 31, 2025 | -36.31% |
| Sep 30, 2025 | 122.82% |
| Jun 30, 2025 | 9.76% |
| Mar 31, 2025 | -23.18% |
| Dec 31, 2024 | 17.42% |
| Sep 30, 2024 | 31.77% |
| Jun 30, 2024 | 1.75% |
| Mar 31, 2024 | 20.64% |
| Dec 31, 2023 | 21.32% |
| Sep 30, 2023 | 20.66% |
| Jun 30, 2023 | 20.08% |
| Mar 31, 2023 | 29.18% |
| Dec 31, 2022 | 17.76% |
| Sep 30, 2022 | 27.95% |
| Jun 30, 2022 | 75.82% |
| Mar 31, 2022 | -24.25% |
| Dec 31, 2021 | -7.21% |
| Sep 30, 2021 | 16.11% |